logo
logo
LH stock ticker logo

Labcorp Holdings Inc.

NYSE•LH
CEO: Mr. Adam H. Schechter
セクター: Healthcare
業種: Medical - Equipment & Services
上場日: 1990-03-29
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs). In addition, the company offers online and mobile applications that enable patients to check test results; online applications for providers, MCOs, and accountable care organizations; specimen collection services; and drug development, medical device, and companion diagnostic development solutions, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was founded in 1995 is headquartered in Burlington, North Carolina.
連絡先情報
358 South Main Street, Burlington, NC, 27215, United States
336-229-1127
www.labcorp.com
時価総額
$21.87B
PER (TTM)
24.8
54.9
配当利回り
1.1%
52週高値
$293.72
52週安値
$209.38
52週レンジ
65%
順位21Top 7.6%
6.0
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
強い • 6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$3.52B+0.00%
直近4四半期の推移

EPS

$2.00+0.00%
直近4四半期の推移

フリーCF

$490.30M+0.00%
直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Revenue Growth 7.2% Revenues reached $13.95B USD, increasing 7.2% driven by 4.4% organic growth and 2.5% acquisition impact.
Operating Income Soars Total Operating Income increased 27.4% to $1.38B USD; Dx margin improved 50 basis points to 16.4%.
Strong Capital Deployment Returned $450.0M USD via share repurchases in 2025; $830.4M remains authorized for future stock buybacks.
Drug Development Support Supported over 85% of new drugs approved by FDA in 2025; launched more than 130 new diagnostic tests.

リスク要因

Reimbursement Rate Pressure PAMA rate reductions resume in 2027, potentially impacting diagnostic service revenues and profitability moving forward.
Personnel Cost Inflation Inability to attract/retain skilled personnel or increased wage growth could cause strategic challenges and higher operating costs.
Cybersecurity Threat Exposure Ongoing cybersecurity threats, including ransomware, require continuous investment to mitigate data compromise and regulatory penalties.
Intellectual Property Litigation Vigorous defense continues in Ravgen patent infringement case; adverse outcomes risk significant costs and reputational harm.

見通し

Specialty Testing Growth Focus Focusing growth on four key specialty areas: oncology, women’s health, autoimmune disease, and neurology expansion planned.
Cell and Gene Therapy Expansion Expanded cell and gene therapy laboratory capacity in Wisconsin to support accelerating drug development pipelines globally.
International Footprint Growth Advanced international strategy via minority stake acquisition in European leader SYNLAB for diagnostic services growth.
Increased Capital Spending Expect capital expenditures to increase to 4.0% of revenues, supporting core business growth and facility upgrades planned.

同業比較

売上高 (TTM)

TEVA stock ticker logoTEVA
$17.26B
+4.3%
LH stock ticker logoLH
$13.95B
+7.2%
DGX stock ticker logoDGX
$11.04B
+11.8%

粗利益率 (最新四半期)

INCY stock ticker logoINCY
90.9%
+1.8pp
UTHR stock ticker logoUTHR
86.9%
-1.5pp
BIIB stock ticker logoBIIB
78.2%
-9.8pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
TEVA$33.27B23.920.1%42.7%
BIIB$26.64B20.67.3%23.6%
NTRA$26.62B-123.4-15.3%8.5%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
1.7%
緩やかな成長
4四半期純利益CAGR
-8.2%
収益性の低下
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年4月27日
|
EPS:-
|
売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書
直近12ヶ月
データなし